Gapping up
In reaction to strong earnings/guidance:
- ADVM +15.7%, EPC +10.1%, IVC +9.9%, DO +5.7%, QSR +2.9%, L +2.8%, CNA +2.7%, AVYA +1%, AGN +0.8%, TSM +0.7%, .
M&A news:
- TCO +52% (Simon Property Group to acquire TCO for $52.50 per share in cash)
- TSLA +7.2% (attributed to piece in Forbes where the magazine makes the case as to why Google (GOOG) could acquire TSLA for $1500/share)
- LB +6% (close to deal to sell Victoria Secret to Sycamore Partners, according to CNBC)
- HCHC +1.1% (says it is in advanced discussions for the potential divestiture of its 100%-owned indirect subsidiaries, Continental Insurance Group Ltd. and Continental General Insurance Company)
Other news:
- VTVT +83.3% (announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes
- ADVM +15.7% (reports new interim data from cohorts 1 and 2 of OPTIC Phase 1 trial of ADVM-022)
- AQST +6.1% (announced FDA acceptance of NDA for Libervant (diazepam) Buccal Film for the management of seizure clusters)
- CRMT +5.6% (to be added to the S&P SmallCap 600)
- KOD +5.5% (provides additional safety, efficacy and durability update from ongoing Phase 1b study of KSI-301)
- INO +5% (receives authorization from the FDA to begin phase 1/2 clinical trial for INO-3107)
- ALEX +3.8% (to be added to the S&P SmallCap 600)
- GNRC +3.6% (gets added to the S&P MidCap 400)
- NTLA +1.7% (presents data from two programs at Keystone Symposia's Engineering the Genome Conference)
Analyst comments:
- CNHI +2.3% (upgraded to Buy from Hold at Deutsche Bank)
- FDX +1.9% (upgraded to Buy from Neutral at UBS)
- ICE +1.5% (upgraded to Buy from Hold at Needham)
- LYFT +1.3% (upgraded to Buy from Neutral at Northcoast)
- NYCB +1.1% (upgraded to Overweight from Neutral at Piper Sandler)